findmyKOL
Clinical trialNCT06941857RecruitingPhase 2Interventional

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

SponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrollment20Pancreatic Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, United States

    Katherine Bever, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Fluorouracil →Leucovorin →Ipilimumab →Irinotecan →NC410Nivolumab →Oxaliplatin →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
4 Sept 2025
Primary completion
31 Dec 2028
Completion
31 Dec 2028
Last update posted
5 May 2026
Registered enrollment
20
Registry id
NCT06941857
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.